Neuroleptic-Induced Parkinsonism: Causes and Symptoms

Neuroleptic-induced parkinsonism develops when antipsychotic medications block too many dopamine receptors in a brain region called the striatum, producing symptoms that look strikingly similar to Parkinson’s disease: stiffness, slowness of movement, and sometimes tremor. It is the most common movement disorder caused by drugs that interfere with dopamine signaling, and it can appear within days or take months to emerge after starting treatment.¹ The condition is reversible in most people once the offending drug is reduced or stopped, but the timeline is unpredictable, and a meaningful subset of cases turn out to be something more complicated.

What Happens in the Brain

Dopamine normally helps coordinate smooth, voluntary movement by acting on receptors in the basal ganglia, a cluster of structures deep in the brain. Antipsychotics work by blocking one type of those receptors, called D2 receptors, which is how they dampen the psychotic symptoms of conditions like schizophrenia. The problem is that the same receptor blockade that reduces hallucinations and delusions also disrupts the motor circuits that depend on dopamine.

Brain-imaging studies using PET scans have quantified the relationship. In patients taking conventional (first-generation) antipsychotics at standard doses, D2 receptor occupancy typically falls between 70% and 89%.² That same study found that patients who developed movement side effects had higher D2 occupancy than those who did not, confirming a dose-response pattern. A separate PET study in first-episode schizophrenia patients put a finer point on it: the likelihood of parkinsonian side effects climbed sharply once D2 occupancy exceeded roughly 78%.³ Meanwhile, a good therapeutic response started appearing at around 65% occupancy. That narrow window between “enough to help” and “enough to cause stiffness” is one reason drug-induced parkinsonism is so common.

The mechanism goes deeper than simple receptor blockade, though. Research in mice has shown that the parkinsonian effect of antipsychotics is specifically triggered by blocking D2 receptors on cholinergic interneurons, a small but influential type of brain cell in the striatum. When those receptors are blocked, the interneurons release excess acetylcholine, which then overstimulates the neurons responsible for movement control.⁴ This acetylcholine surge is a key link in the chain, which is why anticholinergic drugs can partially relieve the symptoms. The broader picture involves disruption across several neurotransmitter systems beyond just dopamine and acetylcholine.¹

Why Some Antipsychotics Are Worse Than Others

Not all antipsychotics carry the same risk. Older, first-generation drugs like haloperidol bind tightly to D2 receptors and drive occupancy into the danger zone at standard clinical doses. Second-generation (atypical) antipsychotics were developed in part to reduce this problem, and some genuinely do. Olanzapine, for example, was shown to produce only mild parkinsonian side effects even at doses that pushed D2 occupancy above 80%, a level that would commonly cause problems with a conventional drug.⁵ Clozapine and quetiapine sit at the lowest-risk end of the spectrum. But not every atypical antipsychotic is gentle on motor circuits; risperidone at higher doses, for instance, can cause parkinsonism at rates comparable to some older drugs.

For years, the dominant explanation for why atypical antipsychotics are kinder to the motor system was the “fast-off” hypothesis: that these drugs let go of D2 receptors quickly, allowing bursts of natural dopamine to get through and keep the motor system running smoothly.⁶ This was an elegant idea, but the evidence has become muddier. A functional kinetics study concluded that typical and atypical antipsychotics are probably not primarily distinguished by how quickly they release from the D2 receptor.⁷ Instead, more recent work suggests that it is how quickly a drug binds to the receptor in the first place (the “on-rate”) that better predicts who gets movement side effects, rather than how quickly it lets go.⁸ Drugs with a faster on-rate may dominate the receptor during brief dips in dopamine, outcompeting the brain’s own signals. The field is still sorting this out, but the practical takeaway is clear: choosing an antipsychotic with a lower propensity for motor side effects is a real clinical lever.

Recognizing the Symptoms

The textbook description of neuroleptic-induced parkinsonism is a bilateral, relatively symmetric pattern of slowness and rigidity, without the resting tremor that characterizes idiopathic Parkinson’s disease. In practice, the presentation is messier than that. About half of patients with drug-induced parkinsonism actually show asymmetric symptoms and resting tremor, making it surprisingly difficult to distinguish from Parkinson’s disease on a bedside exam alone.⁹

The core motor features include:

• Bradykinesia: Movements become slow and effortful, particularly fine motor tasks like buttoning a shirt or writing.
• Rigidity: Muscles feel stiff when a clinician moves the patient’s arm or leg, often described as a “lead pipe” or “cogwheel” resistance.
• Tremor: When present, it tends to be a postural or action tremor rather than the classic pill-rolling rest tremor of Parkinson’s, though rest tremor does appear in a substantial minority.
• Gait changes: A shuffling walk with reduced arm swing, sometimes with difficulty initiating steps.

Beyond these motor signs, people often experience a general blunting of facial expression (sometimes called “masked facies”) and a soft, monotone voice. These changes can be mistaken for depression or the negative symptoms of schizophrenia itself, which complicates matters when the person taking the medication already has a psychiatric diagnosis.

Non-Motor Symptoms and Their Diagnostic Value

Drug-induced parkinsonism does not only affect movement. Patients report fatigue, sleep disturbances, and problems with concentration. However, a comparison between drug-induced parkinsonism and Parkinson’s disease found that certain non-motor symptoms were significantly more prominent in Parkinson’s: urinary urgency, restless legs, daytime sleepiness, and changes in taste or smell all correlated more strongly with true Parkinson’s disease than with the drug-induced version.¹⁰

Smell testing has attracted particular interest as a bedside differentiator. Reduced sense of smell (hyposmia) is one of the earliest features of Parkinson’s disease, often preceding motor symptoms by years. Evidence suggests that preserved smell function can help distinguish “pure” drug-induced parkinsonism from cases where the medication has simply unmasked an underlying neurodegenerative process.¹¹ That said, factors like smoking history and cognitive ability can confound smell testing, so it works best as one piece of a larger clinical picture rather than a standalone test.

Who Is Most at Risk

Certain people are substantially more vulnerable to developing parkinsonism on an antipsychotic. The recognized risk factors include older age, female sex, higher drug doses, longer duration of treatment, the specific drug used, pre-existing cognitive impairment, and a history of other movement disorders like tardive dyskinesia.¹² Older adults are hit hardest because age-related dopamine neuron loss means their motor system is already running on thinner reserves; blocking even a modest fraction of the remaining D2 receptors can tip them into symptoms.

Genetics play a role as well, though the picture is not fully resolved. The enzyme CYP2D6 metabolizes many antipsychotics, and people who carry certain gene variants that make them “poor metabolizers” can end up with higher-than-expected drug levels in their blood. One study found that specific CYP2D6 variants were significantly associated with extrapyramidal side effects, with odds ratios of roughly four- to fivefold for certain genotypes.¹³ Other studies, however, have not found a clear link between CYP2D6 poor-metabolizer status and movement side effects, particularly in patients on stable long-term therapy.¹⁴ The inconsistency likely reflects the fact that genetics are one variable in a system with many others: dose, drug choice, age, and the person’s baseline dopamine reserves all interact.

Separate from drug metabolism, variation in the dopamine receptor gene itself (DRD2/ANKK1) has been linked to susceptibility to akathisia, a related but distinct movement side effect involving restlessness, in patients taking second-generation antipsychotics.¹⁵ This hints at a broader genetic architecture of susceptibility that the field is still mapping out.

Distinguishing It from Parkinson’s Disease

Getting the diagnosis right matters enormously, because the management is completely different. If a person has drug-induced parkinsonism, the goal is to reduce or switch the antipsychotic. If they have Parkinson’s disease, they need dopamine-replacement therapy, and their psychiatric medication may need careful rethinking but not simple withdrawal. Unfortunately, clinical features alone are often unreliable for making the distinction, particularly because many patients taking antipsychotics are older and could plausibly have early Parkinson’s disease at the same time.¹⁶

The traditional approach is a “drug holiday”: stop the suspected medication and see if the parkinsonism resolves. But this is not always safe or practical, particularly for someone whose psychotic symptoms are well-controlled and who might relapse if the drug is withdrawn. Two imaging techniques can help when clinical uncertainty is high.

The first is DAT-SPECT (often called a DaTscan), which measures the density of dopamine transporter proteins in the striatum. In Parkinson’s disease, these transporter levels are reduced because the dopamine-producing neurons are dying. In pure drug-induced parkinsonism, the neurons are intact; the problem is at the receptor level, so the scan typically comes back normal. A meta-analysis found that DAT-SPECT can accurately differentiate between the two conditions, though the authors cautioned that the available studies had methodological limitations.¹⁷

The second is cardiac MIBG scintigraphy, a scan that evaluates the sympathetic nerve supply to the heart. In Parkinson’s disease, these cardiac nerves degenerate early and the scan shows reduced uptake of the tracer. In drug-induced parkinsonism, cardiac nerve function is preserved. One study found that the heart-to-mediastinum uptake ratio was significantly higher in drug-induced parkinsonism patients than in those with Parkinson’s disease.¹⁸ A larger study reported sensitivity and specificity both above 84% for MIBG in distinguishing the two conditions.¹⁹ Neither scan is perfect on its own, but combining clinical information with one or both imaging methods makes the diagnosis substantially more reliable.

How Quickly It Appears and How Long Recovery Takes

The onset of neuroleptic-induced parkinsonism is unpredictable. In one series of patients, the time from first taking the drug to developing symptoms ranged from one week to over a year, with an average around five to six months.²⁰ Symptoms tend to emerge earlier at higher doses and in older patients, but there is no reliable formula to predict exactly when. This wide variability also means that a medication someone has tolerated for months can still produce parkinsonism later, so clinicians need to keep the possibility in mind even well after the initial prescription.

Recovery after stopping the offending drug is usually measured in weeks to a few months. That same study found a recovery period ranging from one to sixteen weeks once the drug was withdrawn.²⁰ Most people improve completely, but a troubling minority do not. When parkinsonism persists or progresses despite stopping the antipsychotic, the usual interpretation is that the drug unmasked underlying Parkinson’s disease that was not yet causing symptoms on its own.²¹ An alternative explanation is that certain drugs may exert a direct toxic effect on the dopamine pathway, though this remains debated.²²

Management Strategies

The first-line approach is reducing the dose of the antipsychotic or switching to one with a lower risk of motor side effects.²³ Clozapine and quetiapine are the antipsychotics most commonly considered when motor side effects are a concern, because they occupy D2 receptors at the lowest rates. Any switch, however, must balance the risk of motor side effects against the risk of psychiatric relapse, which is why these decisions require close collaboration between the patient, prescriber, and sometimes a neurologist.

When changing the antipsychotic is not feasible, anticholinergic medications like benztropine or trihexyphenidyl are sometimes added to counteract the excess acetylcholine signaling that drives the parkinsonian symptoms. These drugs can help with stiffness and tremor, but they come with their own costs. In a study comparing anticholinergic and dopaminergic treatments in Parkinson’s disease (which shares the same motor circuitry), anticholinergic drugs improved motor control but impaired the brain’s ability to register new information, while dopaminergic therapy improved a different aspect of cognition.²⁴ In older adults, anticholinergics carry additional risks including confusion, dry mouth, constipation, and urinary retention, which limits their usefulness in exactly the population most vulnerable to drug-induced parkinsonism in the first place.

How Neuroleptic-Induced Parkinsonism Relates to Other Movement Side Effects

Parkinsonism is just one member of a family of movement disorders linked to antipsychotics. Acute dystonia, which involves sustained involuntary muscle contractions, typically occurs within hours to days of starting or increasing a drug. Akathisia, a distressing inner restlessness that makes a person unable to sit still, also tends to appear early. These early-onset conditions are grouped together as extrapyramidal side effects.²⁵ Tardive dyskinesia, by contrast, emerges late in treatment, usually after months to years, and involves repetitive, involuntary movements like lip smacking or tongue protrusion. Unlike neuroleptic-induced parkinsonism, tardive dyskinesia can be permanent even after the drug is stopped. Clinicians need to distinguish between these conditions because the treatment strategies differ substantially.

Non-Antipsychotic Drugs That Can Cause It

Antipsychotics are the most common culprits, but they are not the only drugs that block dopamine receptors. Metoclopramide, a medication widely prescribed for nausea and gastroparesis, works in part by blocking D2 receptors in the gut and the brain. A large population-based study found that metoclopramide users had roughly double the risk of developing parkinsonism compared to non-users, and the risk was about threefold higher in people who took higher doses.²⁶ Other drugs implicated include prochlorperazine (another anti-nausea medication), certain calcium channel blockers like cinnarizine and flunarizine, and valproic acid. These cases are easy to miss because neither the patient nor the prescriber may think of a stomach medication or a blood-pressure pill as a potential cause of movement problems. Whenever someone develops parkinsonian symptoms, a careful review of all their medications is an essential first step.